Bleeding, Thrombosis and Vascular Biology最新文献

Ankle brachial index for the diagnosis of asymptomatic lower extremity peripheral arterial disease 诊断无症状下肢外周动脉疾病的踝肱指数

Bleeding, Thrombosis and Vascular Biology Pub Date : 2024-07-05 DOI: 10.4081/btvb.2024.128

Francesco Cicconi

{"title":"Ankle brachial index for the diagnosis of asymptomatic lower extremity peripheral arterial disease","authors":"Francesco Cicconi","doi":"10.4081/btvb.2024.128","DOIUrl":"https://doi.org/10.4081/btvb.2024.128","url":null,"abstract":"Peripheral arterial disease (PAD) is a common vascular problem in which progressive narrowing of the arteries due to atherosclerosis reduces blood flow in the lower extremities. This study aimed to assess the prevalence of asymptomatic PAD in patients admitted to an internal medicine ward as well as the risk factors for the onset of the condition. This study included 98 institutionalized patients without a history of PAD. Based on the value of ankle-brachial index (ABI), PAD was classified as mild (0.7-0.9), moderate (0.5-0.7) or severe (<0.5). A detailed lower extremity doppler ultrasound was performed on patients with an ABI index <0.9 to provide more accurate information on peripheral arterial disease. The prevalence of asymptomatic PAD was 10.2%. The mean age of patients with positive ABI was 74. The main risk factors associated with PAD are smoking, chronic kidney disease, dyslipidemia, obesity, hypertension and type 2 diabetes. ABI is a useful and simple tool for detecting asymptomatic PAD. It is also crucial for early diagnosis, prevention and treatment, which can reduce the risk of cardiovascular adverse events as well as limb complications.","PeriodicalId":517891,"journal":{"name":"Bleeding, Thrombosis and Vascular Biology","volume":" 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141674775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identifying novel biomarkers using proteomics to predict cancer-associated thrombosis 利用蛋白质组学鉴定新型生物标记物，预测癌症相关血栓形成

Bleeding, Thrombosis and Vascular Biology Pub Date : 2024-05-16 DOI: 10.4081/btvb.2024.120

Maria J. Fernandez Turizo, R. Patell, Jeffrey I. Zwicker

引用次数: 0

Coagulome and tumor microenvironment: impact of oncogenes, cellular heterogeneity and extracellular vesicles 凝血酶体与肿瘤微环境：癌基因、细胞异质性和细胞外囊泡的影响

Bleeding, Thrombosis and Vascular Biology Pub Date : 2024-05-16 DOI: 10.4081/btvb.2024.109

Nadim Tawil, L. Adnani, Janusz Rak

{"title":"Coagulome and tumor microenvironment: impact of oncogenes, cellular heterogeneity and extracellular vesicles","authors":"Nadim Tawil, L. Adnani, Janusz Rak","doi":"10.4081/btvb.2024.109","DOIUrl":"https://doi.org/10.4081/btvb.2024.109","url":null,"abstract":"Cancer-associated thrombosis (CAT) results from the hemostatic system being dysregulated by the progression of cancer. Despite common clinical manifestations, the mechanisms of CAT may vary greatly because cancers develop along distinct biological trajectories that are imposed by the interaction between the tumor cell genome, the epigenome, the surrounding microenvironment, and the tissue of origin. The coagulome, or repertoire of coagulation effectors, expressed by stromal, inflammatory, and cancer cells at the tumor-vascular interface and systemically, reflects this biological variability. Complex landscapes of coagulant and non-coagulant cellular populations are revealed by single-cell RNA sequencing analyses conducted on unperturbed human cancer tissues. Additionally, through mediators of cell-cell interactions, soluble coagulants, and extracellular vesicles containing tissue factor, podoplanin, and other effectors, coagulomes are projected into the pericellular milieu and systemic circulation. As this complexity is currently outside of the clinical paradigm, one could argue that better CAT management could result from a more individualized analysis of coagulomes in cancer patients.","PeriodicalId":517891,"journal":{"name":"Bleeding, Thrombosis and Vascular Biology","volume":"9 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140969090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Machine learning in cancer-associated thrombosis: hype or hope in untangling the clot 癌症相关血栓的机器学习：是炒作还是解开血栓的希望

Bleeding, Thrombosis and Vascular Biology Pub Date : 2024-05-16 DOI: 10.4081/btvb.2024.123

R. Patell, Jeffrey I. Zwicker, Rohan Singh, Simon Mantha

{"title":"Machine learning in cancer-associated thrombosis: hype or hope in untangling the clot","authors":"R. Patell, Jeffrey I. Zwicker, Rohan Singh, Simon Mantha","doi":"10.4081/btvb.2024.123","DOIUrl":"https://doi.org/10.4081/btvb.2024.123","url":null,"abstract":"The goal of machine learning (ML) is to create informative signals and useful tasks by leveraging large datasets to derive computational algorithms. ML has the potential to revolutionize the healthcare industry by boosting productivity, enhancing safe and effective patient care, and lightening the load on clinicians. In addition to gaining mechanistic insights into cancer-associated thrombosis (CAT), ML can be used to improve patient outcomes, streamline healthcare delivery, and spur innovation. Our review paper delves into the present and potential applications of this cutting-edge technology, encompassing three areas: i) computer vision-assisted diagnosis of thromboembolism from radiology data; ii) case detection from electronic health records using natural language processing; iii) algorithms for CAT prediction and risk stratification. The availability of large, well-annotated, high-quality datasets, overfitting, limited generalizability, the risk of propagating inherent bias, and a lack of transparency among patients and clinicians are among the challenges that must be overcome in order to effectively develop ML in the health sector. To guarantee that this powerful instrument can be utilized to maximize innovation in CAT, clinicians can collaborate with stakeholders such as computer scientists, regulatory bodies, and patient groups.","PeriodicalId":517891,"journal":{"name":"Bleeding, Thrombosis and Vascular Biology","volume":"52 20","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140970569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cancer complicated by thrombosis and thrombocytopenia: still a therapeutic dilemma 癌症并发血栓和血小板减少症：仍是治疗难题

Bleeding, Thrombosis and Vascular Biology Pub Date : 2024-05-16 DOI: 10.4081/btvb.2024.115

Yishi Tan, M. Carrier, Nicola Curry, Michael Desborough, Kathryn Musgrave, Marie Scully, Tzu-Fei Wang, Mari Thomas, Simon J Stanworth

{"title":"Cancer complicated by thrombosis and thrombocytopenia: still a therapeutic dilemma","authors":"Yishi Tan, M. Carrier, Nicola Curry, Michael Desborough, Kathryn Musgrave, Marie Scully, Tzu-Fei Wang, Mari Thomas, Simon J Stanworth","doi":"10.4081/btvb.2024.115","DOIUrl":"https://doi.org/10.4081/btvb.2024.115","url":null,"abstract":"Individuals who have thrombocytopenia and cancer-associated thrombosis (CAT) are difficult to manage because they have a high risk of bleeding and recurrent thrombosis. The International Society on Thrombosis and Haemostasis guidelines for the management of thrombocytopenia in patients with CAT suggest two main approaches: either complete anticoagulation with transfusion support if necessary, or dose-modified anticoagulation while the platelet count is <50×109/L. Nevertheless, rather than being based on information from randomized controlled trials (RCTs), these recommendations were based on expert consensus. Recent research from two different countries has shown how this cohort’s management and results vary widely. While the United Kingdom study, Cancer-Associated Venous Thrombosis and Thrombocytopenia, found no significant differences in bleeding or recurrent thrombosis between full dose and modified dose groups, the North American Thrombocytopenia Related Outcomes with Venous thromboembolism study demonstrated a significantly lower risk of bleeding events in those receiving modified dose anticoagulation compared to full dose, without an increased risk of recurrent VTE. Therefore, an RCT is required to assess the best course of action for patients with CAT and thrombocytopenia. To define the standard of care for the management of patients with CAT and thrombocytopenia, a full-scale trial called the START randomized trial (STrategies for Anticoagulation in patients with thRombocytopenia and cancer-associated Thrombosis) is an international, multi-site pilot study that compares the use of platelet transfusions plus higher dose anticoagulation to modified dose anticoagulation in patients with thrombocytopenia and CAT receiving anticoagulation.","PeriodicalId":517891,"journal":{"name":"Bleeding, Thrombosis and Vascular Biology","volume":"119 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140967601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cancer-associated ischemic stroke: current knowledge and future directions 癌症相关缺血性中风：现有知识与未来方向

Bleeding, Thrombosis and Vascular Biology Pub Date : 2024-05-16 DOI: 10.4081/btvb.2024.117

Ronda Lun, Deborah M. Siegal

引用次数: 0

Factor XI inhibitors: a new option for the prevention and treatment of cancer-associated thrombosis 因子 XI 抑制剂：预防和治疗癌症相关血栓的新选择

Bleeding, Thrombosis and Vascular Biology Pub Date : 2024-05-16 DOI: 10.4081/btvb.2024.118

Marcello Di Nisio, Matteo Candeloro, Nicola Potere, Ettore Porreca, J. I. Weitz

{"title":"Factor XI inhibitors: a new option for the prevention and treatment of cancer-associated thrombosis","authors":"Marcello Di Nisio, Matteo Candeloro, Nicola Potere, Ettore Porreca, J. I. Weitz","doi":"10.4081/btvb.2024.118","DOIUrl":"https://doi.org/10.4081/btvb.2024.118","url":null,"abstract":"Venous thromboembolism (VTE) is a relatively common complication in cancer patients with potentially dire consequences. Anticoagulants are the mainstay of treatment of cancer-associated VTE. The anticoagulants most often used are low-molecular-weight heparin (LMWH) and direct oral factor (F) Xa inhibitors, which include apixaban, edoxaban, and rivaroxaban. Most guidelines recommend primary VTE prophylaxis with LMWH, apixaban, or rivaroxaban after abdominal or pelvic cancer surgery, or in high-risk ambulatory cancer patients. Both oral FXa inhibitors and LMWH have limitations. LMWH requires daily subcutaneous injections, and because of its renal clearance, its use may be problematic in patients with severe kidney disease. The risk of bleeding with oral FXa inhibitors may be higher than with LMWH in patients with intraluminal gastrointestinal or genitourinary cancers. Other problems with oral FXa inhibitors include potential drug-drug interactions and dosing issues in patients with thrombocytopenia or severe kidney or liver disease. Therefore, there remains a need for convenient and safer anticoagulants for VTE treatment in cancer patients. FXI has emerged as a potentially safer target for anticoagulants than FXa because FXI is essential for thrombosis, but mostly dispensable for hemostasis. This review summarizes the currently available therapeutic options for cancer-associated VTE, highlights knowledge gaps, and discusses the potential of FXI inhibitors to address key unmet clinical needs in this vulnerable patient population.","PeriodicalId":517891,"journal":{"name":"Bleeding, Thrombosis and Vascular Biology","volume":"37 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140971340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Welcome to the 12th ICTHIC! 欢迎参加第 12 届国际理论物理和应用化学会议（ICTHIC）！

Bleeding, Thrombosis and Vascular Biology Pub Date : 2024-05-16 DOI: 10.4081/btvb.2024.138

Guest Editors: Anna Falanga, Benjamin Brenner, Alok A. Khorana

引用次数: 0

Patient and public involvement in cancer-associated thrombosis research: necessary or glorified tokenism? 癌症相关血栓研究中的患者和公众参与：必要还是美化？

Bleeding, Thrombosis and Vascular Biology Pub Date : 2024-05-16 DOI: 10.4081/btvb.2024.125

Simon Noble

引用次数: 0

Risk of recurrent venous thromboembolism in cancer patients after discontinuation of anticoagulant therapy 癌症患者停止抗凝治疗后复发静脉血栓栓塞的风险

Bleeding, Thrombosis and Vascular Biology Pub Date : 2024-05-16 DOI: 10.4081/btvb.2024.124

G. E. Raskob

{"title":"Risk of recurrent venous thromboembolism in cancer patients after discontinuation of anticoagulant therapy","authors":"G. E. Raskob","doi":"10.4081/btvb.2024.124","DOIUrl":"https://doi.org/10.4081/btvb.2024.124","url":null,"abstract":"Anticoagulant therapy is recommended for cancer-related venous thromboembolism (VTE). Recurrent VTE prevention is the main goal of this treatment. The majority of evidence-based practice guidelines recommend anticoagulant treatment for at least 6 months. Based on individual assessment of potential benefits and risks, tolerability, drug availability, patient preference, and cancer activity, active cancer patients should continue anticoagulant treatment beyond the 6-month course. When cancer is no longer active or the risk outweighs the benefit, anticoagulant therapy is usually stopped after 3-6 months. Until recently, there was little data on the risk of recurrent VTE in cancer-associated VTE patients after stopping anticoagulants. New results and evidence synthesis have emerged in the last 3 years. Recurring VTE occurs in over 30% in the 5 years after treatment discontinuation. In the first six months, recurrence rates are 10-15%. Recurrences reach 31% at 2 years and stabilize between 2 and 5. Duration of prior anticoagulation does not affect cumulative recurrence. The high risk of recurrent VTE after discontinuing treatment supports guidelines to continue anticoagulant treatment if cancer is active. Stopping anticoagulants after 3-6 months may not be ideal, so randomized clinical trials should be conducted quickly. This review highlights the need to improve cancer patients' primary VTE prevention efforts.","PeriodicalId":517891,"journal":{"name":"Bleeding, Thrombosis and Vascular Biology","volume":"28 13","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140971504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0